From BMI 30: Detachment From the Cash Register? AOK Boss Warns of Billions of Dollars
7 Articles
7 Articles
Treatment with weight loss syringes such as Wegovy or Mounjaro costs several hundred euros a month and usually has to be paid by itself. A cost assumption could burden the GKV with billions.
Weight loss sprays such as Wegovy and Mounjaro could also become a topic for the statutory health insurance companies in the future. However, a cost assumption might have huge financial consequences. The AOK warns against burdens in billions.
AOK CEO Carola Reimann is critical of the acquisition of weight loss syringes in severe obesity. The statutory health insurance companies will have to pay billions of euros.
According to the AOK-Bundesverband (Federal Association of Health Insurance Association), taking over the costs of weight loss injections could burden the statutory health insurance (GKV) with billions of euros in the extreme case. If all GKV-insured obesity patients were treated with it regularly with a body mass index (BMI) of 30 or more, an annual cost of approximately 45 billion euros would be calculated, said AOK head Dr. Carola Reimann to …
Treatment with weight loss syringes such as Wegovy or Mounjaro costs several hundred euros a month and usually has to be paid by itself. A cost assumption could burden the GKV with billions.
Treatment with weight loss syringes such as Wegovy or Mounjaro costs several hundred euros a month. A cost assumption could burden the GKV with billions.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
